Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin.

Alan F. List,Zhuoxin Sun,Amit Verma,John M. Bennett,Rami S. Komrokji,Kathy L. McGraw,Jaroslaw P. Maciejewski,Jessica K. Altman,Puneet Cheema,David F. Claxton,Selina M. Luger,Ryan J. Mattison,Timothy R. Wassenaar,Andrew S. Artz,Charles A. Schiffer,Mark R. Litzow,Martin S. Tallman

Lenalidomide-Epoetin Alfa Versus Lenalidomide Monotherapy in Myelodysplastic Syndromes Refractory to Recombinant Erythropoietin.

2021

Alan F. List
Zhuoxin Sun
Amit Verma
John M. Bennett
Rami S. Komrokji
Kathy L. McGraw
Jaroslaw P. Maciejewski
Jessica K. Altman
Puneet Cheema
David F. Claxton
Selina M. Luger
Ryan J. Mattison
Timothy R. Wassenaar
Andrew S. Artz
Charles A. Schiffer
Mark R. Litzow
Martin S. Tallman

PURPOSEImpaired response to erythropoietin underlies ineffective erythropoiesis and anemia in myelodysplastic syndromes (MDS). We investigated whether treatment with lenalidomide (LEN), which augme...

Keywords:

Lenalidomide
Epoetin alfa
Myelodysplastic syndromes
Internal medicine
Refractory
Ineffective erythropoiesis
Oncology
Erythropoietin
Medicine
recombinant erythropoietin
Anemia

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations